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gional differences ranging from testing 44% to more than 100% of the eligible pa-
tients, implying overuse of diagnostic tests in the latter case. Moreover, there was
a long waiting-time before results of EGFR-mutation tests were available (mean
11.9 days, SD 4.3 days). Considering treatment, on average about 45% of the eligible
patients were treated with EGFR-TKI in the first line. Regional variation was ob-
served ranging from 32% to 84%. Furthermore, extensive treatment variation was
observed, which was not according to current clinical guidelines. CONCLUSIONS:
The probability of testing patients for EGFR and treatments given varied consider-
ably. This did not correspond with current clinical guidelines. Less than 50% of the
eligible patients received EGFR-TKI in the first line. Reasons may be the long wait-
ing-time for test results, physicians experience and individual patient character-
istics. However, the large regional differences plead for optimal use of existing
diagnostic and treatment strategies to improve outcomes for this patient group.
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OBJECTIVES: To determine the extent of social inequality in uptake of prostate
cancer screening in Ireland and compare inequalities across groups for whom the
cost effectiveness of screening is thought to vary. METHODS: A series of decompo-
sition analyses of inequalities in uptake of prostate cancer screening were under-
taken using data collected as part of a large population based survey in the Republic
of Ireland (SLAN 2007). Separate analyses were conducted for individuals differen-
tiated by age on the basis of reported differences in the cost effectiveness of screen-
ing. A range of explanatory variables were used to explore the role of non-need
factors in inequalities including education and possession of private medical
insurance.RESULTS:Overall uptake of prostate screening in men aged 40 years and
over in the preceding 12 months was 23.81%. Uptake was highest among those in
the age group where the cost effectiveness of screening was deemed to be highest
(based on the findings of the European Randomised Study of Prostate Cancer (ER-
SPC) trial). The lowest socioeconomic inequality was also observed among this age
group. The decomposition of the concentration indices showed that possession of
private insurance was the largest determinant of inequality among those 55-69
(36%) and remained a significant determinant among those aged 40-54 (26%) and
aged 70 and over (17%). CONCLUSIONS: The decision to engage with screening is
one likely to be taken in conjunction with a healthcare professional and reflect an
assessment of the expected costs and benefits of screening to the individual.
Where evidence as to the merits of screening is ambiguous and financial incentives
to screen are evident patterns of uptake may emerge that does not represent an
appropriate use of resources and warrant greater scrutiny. KEY WORDS: Prostate
Cancer PSA Test Screening Incidence Diagnosis Concentration Indices Decompo-
sition Analysis
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OBJECTIVES: The European Parliament called for a greater focus on viral hepatitis
and hepatocellular carcinoma (HCC), yet there has been little action on this decla-
ration. We conducted a needs assessment for HCC control and tested needs con-
cordance in five European countries. METHODS: Clinical, policy and patient advo-
cacy stakeholders were purposively sampled from France, Germany, Italy, Spain,
and Turkey. Ten indicators were assessed subjectively: clinical education; early
risk assessment; HBV strategy; HCV strategy; life-style risk factors; national statis-
tics; funding for detection; funding for treatment; political awareness; and public
awareness. Results were compared to a benchmark using a Z-score and concor-
dance tested via the F-test. RESULTS: One hundred participants (response
rate37%) were drawn equally from the 5 countries. Respondents self-identified as
having influence at the local (33%), national (39%), or international (28%) level.
Greatest need is for improvement in life-style risk factors (Z-9.51), political
awareness (Z-7.97), and public awareness (Z-7.67), while the least need is for
improved HBV strategies (Z10.40). Overall, France performed best (Z4.26), and
Turkey worst (Z-2.54). Significant discordances in needs (P0.05) were found for
half of the factors (funding for treatment and detection, public awareness, HBV
strategy and national statistics), but concordance was accepted for the remaining
factors. CONCLUSIONS: We demonstrated a statistical method for conducting a
needs assessment for HCC control in Europe and found that the greatest needs are
for improving life-style risk factors (especially related to obesity and diabetes) and
political and public awareness. Despite being a cost-effective measure, HBV control
strategies are needed the least (mainly due to prior adoption). With both concor-
dant and discordant needs, there are roles for both national and European-wide
efforts in HCC control. For example, the European parliament should lead efforts in
driving political awareness and lifestyle risk factors, while member countries
should focus on public awareness.
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OBJECTIVES:Overall 2506 patients gained access (from a total of 2880 applications)
for oncology treatment from the Cancer Drugs Fund within the first 6 months of its
launch. However, there are significant variations in the number of applications that
different Strategic Health Authorities (SHAs) are able to process and approve. This
study aims to assess the underlying reasons for the observed inter regional vari-
ability in the application rates, processing and outcomes within the Cancer Drugs
Fund from October 2010 to March 2011. METHODS: The results on the application
rates from an audit undertaken by Rarer Cancers Foundation using the Freedom of
Information Act were analysed, especially, the change in application rate over time
and the outcomes of these requests. The analysis led to the development of a
framework to understand the key factors influencing the application rates and its
outcomes, which was then validated through a telephone survey of key SHAs in
2011. RESULTS: Along with significant variations in the application rate, there
appears to be a north-south divide, with SHAs in the south of England approving a
lower proportion of applications. Some of the underlying reasons were identified to
be linked with administration costs, levels of routine access to cancer treatments
(which itself vary according to the area of the country) and ‘timely’ decision-mak-
ing ability. CONCLUSIONS: Some of the notable practices identified towards expe-
diting the processing of applications can form recommendations for robust process
development in future for the upcoming clinical commissioning consortia to guide
their commissioning activities. Future steps can include benchmarking of their
application approval rates by clinical commissioning consortia (and SHAs until
2013) against that in other region and take action to identify the outliers and ad-
dress the causes of this.
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OBJECTIVES: Substantial differences in cancer-related mortality rates among the
16 provinces of Poland exist. Over the last 10 years the differences between the
highest and the lowest observed standardized mortality rates varied at 33.9% to
54.2% in female population and at 24.1% to 40.9% in male population. The differ-
ences in mortality rates cannot be explained only by differences in cancer inci-
dence rates among the provinces since weak correlation between both this values
exist (Pearson’s correlation r0.33 and r0.36 in male and female population, re-
spectively). There are also substantial differences in availability of oncology care
among the provinces since to some extent each of 16 regional departments of the
National Health Fund (NHF) pursues its own health policy. The aim of this study
was to estimate whether the differences in availability of oncology care are respon-
sible for differences in cancer-related mortality among the provinces of Poland.
METHODS: We used NHF data on contracts for oncology hospital and ambulatory
care in 2008 and the National Cancer Registry (NCR) data on age-standardized
mortality rates due to cancer in 2008. Data on hospital and ambulatory care and
incidence data for each province were used to estimate availability of oncology care
per cancer patient. Incidence data were used due to lack of cancer precise preva-
lence data. RESULTS: We have found no strict correlation between mortality rates
and availability of hospital care with Pearson’s correlation r-0.01 and r-0.05 in
male and female population, respectively. Surprisingly weak positive correlations
between mortality rates and availability of ambulatory care were found with Pear-
son’s correlation r0.36 and r0.45 in male and female population, respectively.
CONCLUSIONS: Further research, extended beyond simple relation between clin-
ical outcomes and health care service financing is needed to explore inter-prov-
inces variability. International Research Project on Financing Quality in Healthcare
InterQuality, is aimed to address those discrepancies in health care.
PCN165
A FIRST ESTIMATE OF THE INCREMENTAL IMPACT OF MALES HPV
VACCINATION ON HPV-RELATED DISEASES IN EUROPE
Bresse X1, Largeron N1, Marty R2, Roze S2
1Sanofi Pasteur MSD, Lyon, France, 2HEVA, Lyon, France
OBJECTIVES: Human Papilloma Virus (HPV) vaccination programs among women
have been successfully implemented in Europe. Burden of HPV-related cancers is
rising in Europe in men and represents around 30% of the overall HPV-related
burden in both genders. Vaccinating girls have an indirect protective impact on
males but doesn’t avoid the whole HPV burden. Study objective was to have a first
estimate of the incremental benefits of vaccinating males and females compared to
females only, in Europe. METHODS: An Excel-based model was developed to esti-
mate impact of vaccinating boys and girls with a quadrivalent-HPV6/11/16/18 vac-
cine on HPV-related diseases: anal, penile, head and neck, vaginal, vulvar and
cervical cancers and genital warts. Epidemiological reductions due to vaccination
were derived from a US dynamic transmission model. Epidemiological data and
demographic inputs came from published literature. The analysis estimates the
incremental clinical benefits of adding a cohort of 12-years old boys to a 12-years
old girls vaccination program. Seventy percent vaccine coverage rates were as-
sumed for both strategies. RESULTS: A validation of this model was achieved by
being able to replicate US dynamic model results (number of cases avoided). In
Europe, female-only vaccination would result in a 61% reduction in males HPV-
related cancers (at steady state; 100 years). Adding a cohort of boys would increase
this result to 86% and would avoid significant additional HPV-related diseases
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